PharmaCyte Biotech, Inc.

- 15 APR 2014
Nuvilex Contracts With Clinical Network Services Pty Ltd for Late-Phase Clinical Trials in Pancreatic Cancer
SILVER SPRING, Md., April 15, 2014 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (NVLX), a clinical-stage international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, announced today that it has contracted Clinical Network Services Pty Ltd (CNS), a fully integrated drug development company based in Australia, New Zealand and the United
Read more →
- Posted in
- News
- 10 APR 2014
Nuvilex Engages ViruSure to Establish Cell Banks for Phase 2b Clinical Trials in Pancreatic Cancer
SILVER SPRING, Md., April 10, 2014 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (NVLX), a clinical-stage international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, reported today that it has signed a Master Services Agreement with ViruSure GmbH, located in Vienna, Austria, to develop and maintain Master, Working and End of
Read more →
- Posted in
- News
- 08 APR 2014
Medical Marijuana Sciences’ Dr. Mark L. Rabe Speaks at ASA Medical Cannabis Unity Conference in Washington DC
Cell-in-a-Box(R) Live-Cell Encapsulation and Anti-Cancer Properties of Cannabinoids Emphasized

SILVER SPRING, Md., April 8, 2014 (GLOBE NEWSWIRE) — Medical Marijuana Sciences, Inc., a subsidiary of PharmaCyte Biotech, Inc. (NVLX), a clinical-stage international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, reported today that Dr. Mark L. Rabe’s presentation at
Read more →
- Posted in
- News
- 01 APR 2014
Nuvilex Selects Translational Drug Development (TD2) to Advance Treatment for Pancreatic Cancer
PharmaCyte Biotech Retains TD2 to Conduct Preclinical and Clinical Studies

SILVER SPRING, Md., April 1, 2014 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (NVLX), a clinical-stage international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, announced today that it has signed a Master Services Agreement with Translational Drug Development (TD2)
Read more →
- Posted in
- News
- 25 MAR 2014
Nuvilex to Present at National Medical Cannabis Unity Conference in Washington DC
Dr. Mark L. Rabe to Speak on “Unique Applications for Cannabinoid Chemotherapy Therapy”

SILVER SPRING, Md., March 25, 2014 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (NVLX), a clinical-stage international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, announced today that holistic and medical marijuana expert Dr. Mark L. Rabe,
Read more →
- Posted in
- News
- 20 MAR 2014
Nuvilex Contracts with Austrianova for cGMP-Compliant Cell-in-a-Box® Encapsulation of Cells for Clinical Trials
Manufacturing Agreement Signed by PharmaCyte Biotech and Austrianova

SILVER SPRING, MD, March 20, 2013 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (OTCQB: NVLX), an international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, announced today that it has contracted with Austrianova Singapore (Austrianova), a subsidiary of SG Austria in
Read more →
- Posted in
- News
- 11 MAR 2014
Nuvilex Appoints CEO and President of Austrianova to Scientific Advisory Board
Dr. Brian Salmons Indispensable for Development of Cannabis-based Cancer Treatments

SILVER SPRING, MD, March 11, 2014 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (OTCQB: NVLX), an international biotechnology company providing cell and gene therapy solutions for the treatment of deadly diseases, announced today that its subsidiary, Medical Marijuana Sciences, Inc., has appointed Brian Salmons, Ph.D.,
Read more →
- Posted in
- News
- 07 MAR 2014
Nuvilex Appoints Dr. Garret L. Yount to Its Subsidiary’s Scientific Advisory Board
Dr. Yount’s Expertise in Preclinical Use of Cannabinoids Against Cancer Cells Invaluable for Developing Cannabinoid-Based Cancer Treatments

SILVER SPRING, Md., March 7, 2014 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (NVLX), an international biotechnology company providing cell and gene therapy solutions for the treatment of deadly diseases, announced today that its subsidiary, Medical Marijuana Sciences,
Read more →
- Posted in
- News
- 20 FEB 2014
Nuvilex Announces $27 Million Funding Commitment With Institutional Investor to Advance Late Phase Clinical Trials
$2 Million Initial Investment Completed

SILVER SPRING, Md., Feb. 20, 2014 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (NVLX), an international biotechnology company providing cell and gene therapy solutions for the treatment of deadly diseases, announced today that it has entered into a stock purchase agreement with Lincoln Park Capital Fund, LLC (Lincoln Park), a
Read more →
- Posted in
- News
- 03 FEB 2014
Nuvilex to Use Proprietary Cell-in-a-Box Technology to Develop Marijuana-Based Cancer Treatments
SILVER SPRING, Md., Feb. 3, 2014 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (NVLX), an international biotechnology company providing cell and gene therapy solutions for the treatment of deadly diseases, announced today that its subsidiary, Medical Marijuana Sciences, Inc., plans to use the unique and proprietary cellulose-based live-cell encapsulation technology known as Cell-in-a-Box(TM) to develop treatments
Read more →
- Posted in
- News

Press Releases

Cell-in-a-Box(R) Live-Cell Encapsulation and Anti-Cancer Properties of Cannabinoids Emphasized

PharmaCyte Biotech Retains TD2 to Conduct Preclinical and Clinical Studies

Dr. Mark L. Rabe to Speak on “Unique Applications for Cannabinoid Chemotherapy Therapy”

Manufacturing Agreement Signed by PharmaCyte Biotech and Austrianova

Dr. Brian Salmons Indispensable for Development of Cannabis-based Cancer Treatments

Dr. Yount’s Expertise in Preclinical Use of Cannabinoids Against Cancer Cells Invaluable for Developing Cannabinoid-Based Cancer Treatments

$2 Million Initial Investment Completed